Get the Stockscreener App
12.22
1.69%
-0.21
After Hours:
12.14
-0.08
-0.65%
Delcath Systems Inc stock is traded at $12.22, with a volume of 298.91K.
It is down -1.69% in the last 24 hours and down -0.16% over the past month.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$12.43
Open:
$12.44
24h Volume:
298.91K
Relative Volume:
0.65
Market Cap:
$421.85M
Revenue:
$90.44M
Net Income/Loss:
$561.00K
P/E Ratio:
2,036.67
EPS:
0.006
Net Cash Flow:
$19.19M
1W Performance:
-4.61%
1M Performance:
-0.16%
6M Performance:
+16.05%
1Y Performance:
+7.19%
1-Day Range:
$12.12
$12.57
1-Week Range:
$12.12
$12.97
52-Week Range:
$8.12
$13.74
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
12.22 | 421.85M | 90.44M | 561.00K | 19.19M | 0.006 |
ABT
Abbott Laboratories
|
103.06 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.25 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.21 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.25 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.63 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
TradingKey - TradingKey
DCTH|Delcath Systems Inc|Price:12.220|Chg%:-0.210 - TradingKey
Delcath Systems, Inc. Revenue Breakdown – LS:A2PT5P - TradingView
Press Release: Delcath Systems to Host Second Quarter 2026 Earnings Call - Moomoo
Delcath Systems sets Aug. 6 briefing on second-quarter results - Stock Titan
Delcath Systems to Host Second Quarter 2026 Earnings Call - Yahoo Finance
Understanding Momentum Shifts in (DCTH) - Stock Traders Daily
Delcath Systems announces inducement grants - Medical Buyer
ETFs Investing in Delcath Systems, Inc. Stocks - TradingView
Four Delcath Employees Receive Stock Awards Tied to Vesting Dates - Stock Titan
Delcath Systems grants 17,000 inducement RSUs to four new hires - Bitget
Delcath Systems (DCTH) Slides 3.77% as Stock Tests Key Support LevelsFlat Correction - dars.gov.et
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued - GuruFocus
CCORF Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Delcath Systems begins Phase 2 breast cancer trial - grafa.com
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer - BioSpace
Delcath doses first patient in breast cancer trial in Milan By Investing.com - Investing.com Nigeria
Delcath doses first patient in breast cancer trial in Milan - Investing.com
$13.513 | Delcath Systems, Inc. Common Stock (DCTH) Stock Price Today - Binance
Delcath Systems (DCTH) Gains 2.12% as Stock Approaches Key Resistance LevelGEX Level - DonanımHaber
DCTH Q1 2026 Earnings: EPS Surprises to the Upside as Company Advances Core PipelineEarnings Per Share - dars.gov.et
DCTHDelcath Systems Inc Options - Finviz
Price to sales forward of Delcath Systems, Inc. – NASDAQ:DCTH - TradingView
Avoiding Lag: Real-Time Signals in (DCTH) Movement - Stock Traders Daily
Delcath Systems, Inc.(NasdaqCM:DCTH) added to Russell Microcap Value Benchmark Index - marketscreener.com
Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 2000 Value Benchmark - marketscreener.com
Price to book forward of Delcath Systems, Inc. – SWB:DV3R - TradingView
Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 2000 Value-Defensive Index - marketscreener.com
Price to earnings forward of Delcath Systems, Inc. – NASDAQ:DCTH - TradingView
Enterprise value to revenue forward of Delcath Systems, Inc. – SWB:DV3R - TradingView
Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Delcath Systems, Inc. – NASDAQ:DCTH - TradingView
Mettler-Toledo (MTD) soars 3.3%: Is further upside left in the stock? - MSN
Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 2000 Defensive Index - marketscreener.com
Delcath Systems, Inc. Actuals & Estimates (FWB:DV3R) - TradingView
Delcath Systems, Inc. Actuals & Estimates (NASDAQ:DCTH) - TradingView
Delcath Systems, Inc. Actuals & Estimates (LS:A2PT5P) - TradingView
DCTH Forecast — Price Target — Prediction for 2027 - TradingView
Delcath Systems Inc (DCTH) Institutional Confidence - TradingKey
Delcath Systems (DCTH) Surges 5.6% on Above-Average Volume, Tests Key ResistanceChart Pattern Alerts - dars.gov.et
Delcath Systems, Inc. (DCTH) reports Q1 loss, misses revenue estimates - MSN
Delcath Systems Inc (DCTH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Delcath Systems (DCTH) Dips 2% as Stock Approaches Critical SupportHigh Volume Stocks - dars.gov.et
Delcath Systems Inc (DCTH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Delcath Systems Inc (DCTH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Delcath Systems Inc (DCTH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Delcath Systems Inc (DCTH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Delcath Systems Inc (DCTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Delcath Systems Inc (DCTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Delcath Systems (DCTH) Rallies 3.7%—Testing Key Resistance at $12.57Volume Breadth - dars.gov.et
Q1 2026 Delcath Systems Inc Earnings Call Transcript - GuruFocus
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Delcath Systems Inc Stock (DCTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sylvester John Richard | Director |
Nov 21 '25 |
Buy |
8.89 |
4,386 |
38,992 |
14,936 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER |
Nov 11 '25 |
Buy |
8.53 |
11,500 |
98,049 |
330,834 |
1.90%
2.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):